Massachusetts lawmakers have approved a bill to establish a pilot program for the regulated therapeutic use of psychedelics. And two committees have separately held hearings to discuss additional psilocybin-related measures.
Less than two weeks after advancing out of the legislature’s Joint Committee on Mental Health, Substance Use and Recovery Hearing, the pilot program legislation from Sen. Cindy Friedman (D) moved through the Joint Committee on Health Care Financing on Tuesday with a “do pass” recommendation.
The bill, S.1400, is light on specifics, leaving many details of the pilot program up to regulators with the Department of Public Health (DPH). But in general, it calls for a “pilot program to allow for the monitored mental health care of clinically appropriate patients using psychedelic materials.”
It would involve the “on-site administration by a multi-disciplinary care team in a supervised licensed mental health clinic setting.”
DPH could only issue licenses for up to three health facilities to administer and study the psychedelics in the state. They would be tasked with “establishing the best and safest clinical practices for psychedelic mental health treatment programs in the commonwealth and for the purposes of collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy.”
“Eligible pilot
Read full article on Marijuana Moment
